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KCl cotransportSickle cell disease (SCD) in patients of HbSC genotype is considered similar, albeit milder, to that in homozygous
HbSS individuals— butwith little justiﬁcation. In SCD, elevated red cell cation permeability is critical as increased
solute loss causes dehydration and encourages sickling. Recently, we showed that the KCl cotransporter (KCC)
activity in red cells from HbSC patients correlated signiﬁcantly with disease severity, but that in HbSS patients
did not. Two transporters involved in red cell dehydration, the conductive channels Psickle and the Gardos chan-
nel, behaved similarly in red cells from the two genotypes, but were signiﬁcantly less active in HbSC patients. By
contrast, KCC activitywas quantitatively greater inHbSC red cells. Results suggest that KCC is likely to have great-
er involvement in red cell dehydration in HbSC patients, which could explain its associationwith disease severity
in this genotype. Thiswork supports the hypothesis that SCD inHbSCpatients is a distinct disease entity to that in
HbSS patients. Results suggest the possibility of designing speciﬁc treatments of particular beneﬁt to HbSC pa-
tients and a rationale for the development of prognostic markers, to inform early treatment of children likely
to develop more severe complications of the disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Sickle cell disease (SCD) is one of the commonest severe inherited
disorders affecting millions of people worldwide (Piel et al., 2013).
Complications of the disease arise from the presence in patients' red
cells of the abnormal haemoglobin (Hb), HbS, which has a single
amino acid substitution compared to normal adult Hb, HbA. In HbS, va-
line replaces glutamic acid in the 6th codon of the β chain, with loss of a
negative charge (Bunn and Forget, 1986). On deoxygenation, this sub-
stitution allows neighbouring molecules of HbS to adhere, forming
rigid polymerswhich distort the shape of the red cell. The complications
of SCD all follow from polymerisation of HbS, although in many cases
details of the pathogenesis remain unclear.
About two-thirds of SCD patients are homozygous for HbS (HbSS ge-
notype, or disease, sometimes referred to as sickle cell anaemia, SCA)
(Rees et al., 2010). Co-inheritance of a second abnormal Hb, HbC, in
which lysine replaces glutamic acid at the same position of the β
chain, along with HbS produces the heterologous HbSC genotype
(HbSC disease) (Nagel and Lawrence, 1991; Nagel and Steinberg,
2001). HbSC individuals account for about one-third of SCD patients
(Nagel and Steinberg, 2001) and thereby represent a sizeable patient
cohort. The vast majority of laboratory and clinical studies on SCD,. This is an open access article underhowever, including those on red cell cation homeostasis, have been car-
ried out on HbSS patients, with HbSC patients being largely and unjus-
tiﬁably neglected.
BothHbSS andHbSCdisease have profound clinical impact, although
those homozygous for HbC (HbCC) are largely asymptomatic (Nagel
and Steinberg, 2001). Complications are multiple including chronic
anaemia, pain and organ dysfunctionwith signs dependent on the iden-
tity of the affected organ - stroke, acute chest syndrome, nephropathy,
osteonecrosis, dactylitis, etc. (Rees et al., 2010; Steinberg et al., 2001;
Nagel and Platt, 2001). Between individuals, clinical severity is marked-
ly heterogeneous, with the health of some patients being severely com-
promised, whilst others present with a less severe disease or even a
subclinical course. In many cases it is not understood why. Generally,
HbSC disease is milder, though it still presents with signiﬁcant morbid-
ity (Platt et al., 1991; Nagel et al., 2003). For example, life expectancy of
HbSC individuals is markedly reduced (Platt et al., 1994), and some
complications of SCD, like proliferative retinopathy (Condon and
Serjeant, 1970), are over-represented in HbSC patients.
Intracellular cation homeostasis in red cells is maintained mainly by
active movement of Na+ and K+ via the ATP-driven Na+/K+-pump
coupled with a relatively low passive permeability through various
transport pathways. Together these set intracellular [K+] at about
100 mM and Na+ at about 15 mM (Joyce, 1958). A major feature of
red cells from SCD patients, however, is their abnormally high cation
permeability. This characteristic is important, as it causes red cells tothe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. A schematic diagram summarising themain cation pathways involved in solute loss from red cells in patients with sickle cell disease (SCD). In deoxygenated red cells (right), HbS
polymerises causing morphological sickling and activation of (i) Psickle, a deoxygenation-induced cation conductance. Its main effect is to allow entry of Ca2+ which activates a second
transport pathway, (ii) the Ca2+-activated K+ channel or Gardos channel, which mediates conductive K+ loss at high rates. In oxygenated red cells (left), Psickle and the Gardos channel
are inactive. A third transport pathway, (iii) the KCl cotransporter (KCC) mediates obligatorily coupled efﬂux of K+ and Cl−. It is present at higher activities in HbS-containing red cells,
compared to those from normal (HbAA) individuals. Activity is further enhanced by low pH, swelling and urea. KCC may remain active in deoxygenated sickle cells, with Mg2+ loss via
Psickle, further increasing its activity. The relative importance of these pathways in red cells from HbSC and HbSS patients appears to differ which may be important in pathogenesis.
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centration of HbS ([HbS]). As the lag time to polymerisation of deoxy-
genated HbS is inversely proportional to a very high power of [HbS]
(Eaton and Hofrichter, 1987), any shrinkage markedly increases the
likelihood of polymerisation as red cells traverse hypoxic regions of
the circulation. Considerable effort has been expended on investigating
this high cation permeability (Tosteson et al., 1952; Joiner et al., 1993;
Gibson and Ellory, 2002; Lew and Bookchin, 2005), and designing po-
tential inhibitors (eg Stocker et al., 2003), but studies are restricted al-
most exclusively to red cells from HbSS patients.
Threemain transport systems are involved in solute loss and red cell
dehydration (summarised in Fig. 1: Lew and Bookchin, 2005): the
deoxygenation-induced cation conductance (sometimes termed Psickle),
the Ca2+-activated K+ channel (or Gardos channel) and the KCl
cotransporter (KCC). Psickle is activated by deoxygenation and red cell
shape change (Tosteson, 1955; Mohandas et al., 1986; Joiner, 1993). It
allows entry of Ca2+ (Rhoda et al., 1990) which may then activate the
third transporter (Lew et al., 1997), the Gardos channel, with conduc-
tive K+ loss at high rates, and Cl− following separately through separate
anion channels. KCC mediates coupled movements of K+ and Cl−
(Ellory et al., 1982; Lauf et al., 1992; Gillen et al., 1996). Its activity is ab-
normally elevated in red cells fromHbSS patients (Brugnara et al., 1986;
Crable et al., 2005), and it also responds differently to modulatory stim-
uli such as O2 tension (Gibson et al., 1998), when compared to red cells
from normal HbAA individuals. It may also be further stimulated by
Mg2+ depletion via Psickle (Ortiz et al., 1990; Delpire and Lauf, 1991).
As noted above, with the exception of a few studies involving a handful
of HbSC patients (Canessa et al., 1986), our understanding of these
systems comes from work on red cells from SCA patients. The be-
haviour of red cells from HbSC patients and management of disease
is largely extrapolated from these studies on HbSS - but this may not
be justiﬁed.
Our recent study comparing clinical parameters and K+ transport in
red cells from HbSS and HbSC patients indicated signiﬁcant differences
between the two genotypes (Rees et al., 2015). In particular, KCC activ-
ity was higher in HbSC patients with more severe forms of SCD (Rees
et al., 2015), whilst the same was not true for KCC activity in red cells
fromHbSS patients. These ﬁndings, alongwith differences in clinical pa-
thology, support the hypothesis that HbSC disease is a distinct clinical
entity. Since changes in red cell membrane permeability represent an
early event in SCD pathogenesis, with a direct association with HbS po-
lymerisation, further work on membrane transport in red cells from
HbSC patients is an imperative. In this report, we characterise more
fully the behaviour of the main K+ transport systems in red cells from
HbSC patients and highlight important differences in comparison with
red cells from patients with SCA.2. Materials and Methods
2.1. Chemicals
Bumetanide, 3-[N-morpholino] propane sulphonic acid (MOPS),
nystatin, ouabain, OptiPrep and salts were purchased from
Sigma Chemical Co. (Poole, Dorset, UK). Clotrimazole and 4-(2-
hydroxyethyl)-1-piperazine ethane sulphonic acid (HEPES) were pur-
chased from Calbiochem (Nottingham, UK). 86Rb+ was supplied by
Perkin Elmer (Beaconsﬁeld, UK).
2.2. Sample Collection and Handling
Blood sampleswere taken for routine tests according to clinical indi-
cations from patients at King's College Hospital, homozygous HbSS or
heterozygous HbSC for sickle cell disease (SCD), using the anticoagulant
EDTA. During the course of this study, around two hundred patients of
the HbSC genotype attended the sickle cell clinics at KCH, compared to
about four hundred of HbSS genotype. Samples were kept at 4 °C until
use within 48 h. The study was approved by the National Research
Ethics Committee London-East (reference 11/LO/0065). For some ex-
periments, after routine haematological testing, discarded and
anonymised blood was analysed, under the approval of the local ethics
committee. All research was conducted in accordance with the Helsinki
Declaration of 1975, as revised in 2008.
2.3. Solutions and Tonometry
The standard saline (Cl-MBS) comprised (in mM): 145 NaCl, 1.1
CaCl2, 5 glucose and 10 MOPS, (pH 7.4 at 37 °C; 290 ± 5 mOsm.kg−1
H2O). For experiments in which Cl− dependence of K+ inﬂux was ex-
amined, NO3−containing salts replaced those containing Cl− (N-MBS).
The wash solution to remove unincorporated 86Rb+ comprised isotonic
MgCl2 (107 mM), buffered with MOPS (10 mM), pH 7.4 at 4 °C (Mg-
MBS). Stock solutions of bumetanide (10 mM), ouabain (10 mM) and
clotrimazole (CLT; 5 mM) were prepared in 100 mM Tris base, distilled
water and DMSO, respectively. In most experiments whole blood was
washed ﬁve times in N-MBS to remove Cl−, plasma and buffy coat.
Red cell suspensions at 20% haematocrit (Hct) in N-MBS were placed
in tonometers (Eschweiler, Kiel, Germany) ﬂushed with warm, humid-
iﬁed gas mixtures for 20 min at 37 °C to equilibrate at the requisite O2
tension before ﬂux measurements and red cell shape analysis (Speake
et al., 1997). Gas mixtures were made using a Wösthoff gas mixing
pump (Speake et al., 1997). For ﬂuxmeasurements, red cell suspensions
were then diluted ten-fold into ﬂux tubes, still equilibrated at the re-
quiredO2 tension. To analyse red cell shape, aliquots of cellswere placed
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microscopy.2.4. K+ Flux Measurements
To determine the activity of the K+ transport pathways, K+ inﬂux
was measured at 37 °C using 86Rb+ as a congener for K+ (Dunham
and Ellory, 1981; Hannemann et al., 2011). Red cells were taken from
tonometers and diluted 10-fold into saline, pre-equilibrated at the ap-
propriate O2 tension, and, unless otherwise stated, at 260 mOsm.kg−1
and pH 7. 86Rb+ was added in 150 mM KNO3 to give a ﬁnal [K+] of
7.5 mM. Typically, three ﬂux conditions were used: (i) Cl-MBS, (ii) Cl-
MBS with clotrimazole and (iii) N-MBS with clotrimazole. Ouabain
(0.1 mM) and bumetanide (0.01 mM) were present in all experiments
to obviate any K+ transport through the Na+/K+ pump and the Na+-
K+-2Cl− cotransporter, respectively. After incubationwith radioisotope
for 10 min, red cells were washed ﬁve times in ice-cold Mg-MBS wash
solution to remove extracellular 86Rb+. Following the ﬁnal wash, the
cell pellet was lysed with Triton X-100 (0.1%) and protein precipitated
with trichloroacetic acid (5%). Activity was then measured as Čerenkov
radiation by liquid scintillation (Packard Tri-carb 2100TR). Psickle was
assayed as the deoxygenation-induced, clotrimazole-independent K+
inﬂux measured in the absence of Cl− (condition iii); Gardos channel
activity as the CLT-sensitive (0.005 mM) K+ inﬂux (using conditions i
& ii); and KCC activity was assayed as Cl−dependent K+ inﬂux (using
ﬂux conditions ii & iii). For CLT, dissolved in DMSO, appropriate controls
were all treated with the same concentration of solvent (0.1% ﬁnal). Ei-
ther microhaematocrit determination or the cyanohaemoglobin meth-
od was used to measure the Hct with appropriate samples for this
taken before the start of each experiment.2.5. Density Separation
Whole blood was washed three-times in HEPES-buffered saline
(HBS, comprising in mM: 140 NaCl, 5 KCl, 0.15 MgCl2, 10 HEPES, pH
7.4 at room temperature) to remove plasma and buffy coat. Red cells
were separated according to density into light, intermediate and
dense fractions by centrifugation on gradients of OptiPrep. Stock solu-
tion of OptiPrep (60% w/v iodixanol) was diluted to 40% w/v in 3xHBS
(HBS containing 30 mM HEPES) before diluting further in HBS to pro-
duce the desired densities. Densities used depended on the blood sam-
ples andwere b1.095± 0.001 and N1.098± 0.001 g.ml−1 for HbSC and
b1.089±0.001 and N1.093±0.002 g.ml−1 for HbSS to recover the light
and dense fraction, respectively. 150 μl of loosely packed red cells were
layered over 0.4 ml gradient in 1.5 ml tubes and centrifuged at 700 g at
10 °C for 5 min (Denley BR401 bench-top centrifuge, swing-out rotor).
Fractionswere isolated, washed in HBS and, where necessary, separated
on a different gradient in order to obtain the light, intermediate and
dense fraction. Light and dense cell fractions were divided into two,
with half kept as controls and half treated subsequently with nystatin.Fig. 2.ConductiveK+ pathways and sickling in red cells fromHbSCpatients. Red cells (20%
haematocrit, Hct) were equilibrated in Eschweiler tonometers at the indicated oxygen
tension for 20 min. Red cell aliquots were then ﬁxed in 0.3% glutaraldehyde and percent-
age sickling assessed by light microscopy. Further aliquots were diluted ten-fold into test
tubes for measurement of K+ inﬂux (given as mmol K+.(l cells.h)−1). Psickle activity is de-
ﬁned as the deoxygenation-induced K+ inﬂux in Cl− free saline in the presence of ouabain
(100 μM), bumetanide (10 μM) and clotrimazole (CLT; 5 μM), and the Gardos channel ac-
tivity as the CLT-sensitive K+ inﬂux in the presence of ouabain and bumetanide.
(a) Oxygen dependence of sickling, Psickle and Gardos channel. Data are presented as
means± S.E.M., n= 4–8. (b, c) Pearson correlation of Psickle and Gardos channel activities
with % sickling. Correlations were r = 0.302 (p b 0.01) for Psickle and r = 0.305 (p b 0.01)
for the Gardos channel.2.6. Nystatin Treatment
Density separated red cells were washed three-times in HK-HBS
(comprising in mM: 135 KCl, 10 NaCl, 10 glucose, 10 HEPES, pH 7.4 at
RT; 290 ± 5 mOsm.kg−1) before treatment on ice for 45 min with nys-
tatin (0.1 mg.ml−1) at 5% Hct in HK-HBS containing 25 mM sucrose.
Nystatin was then removed using seven washes with HK-HBS contain-
ing sucrose (25 mM) and bovine serum albumin (1 mg.ml−1) at room
temperature. Prior to K+ inﬂuxmeasurements, nystatin-treated andun-
treated red cells were washed four times with ice-cold N-MBS, adjusted
to 20%Hct. Theywere then diluted ten-fold into saline formeasurement
of K+ inﬂux, as described above.2.7. Statistics
Results are presented asmeans± S.E.M. of n observations in red cell
samples taken from different individuals. Where appropriate, compari-
sons were made using unpaired (Figs. 3–5, 7) and paired (Fig. 8) two-
tailed Student's t-tests. Correlationsweremade using the Pearson corre-
lation test. The level of signiﬁcance used was p b 0.05.
3. Results
3.1. Sickling and Conductive K+ Transport in Red Cells FromHbSC andHbSS
Patients
Sickling and conductive K+ transport were measured in air and
across the physiological range of O2 tensions in red cells from HbSC pa-
tients. Morphological shape change became apparent as O2 tensionwas
reduced to about the P50 of Hb. Several aspects of K+ transport in HbSC
cells were also sensitive to O2 tension (Fig. 2a). At arterial O2 tensions,
the deoxygenation-induced cation conductance, or Psickle, and the
Gardos channel showed low activities. As for sickling, these increased
as O2 tensions were reduced to levels at which Hb becomes deoxygen-
ated. Activities of both were maximal at the lowest O2 tensions and
also correlated with degree of cell sickling (Fig. 2b & c: Pearson
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p = 0.0012 for Gardos channel).
Sickling and the activities of K+ transportwere compared in red cells
from HbSC and HbSS patients in more detail. In oxygenated conditions,
the percentage of sickled red cells was 8.4 ± 1.1% and 0.2 ± 0.04%
(Fig. 3b) in HbSS and HbSC patients, respectively. The higher values in
patients with SCA were presumably due to the presence of irreversibly
sickled cells (ISCs) which were observed in oxygenated HbSS samples
butwere absent in those fromHbSC individuals. In both genotypes, sick-
ling was observed in around 80% of red cells on deoxygenation (Fig. 3b).
The residual K+ inﬂux in Cl− free media was also measured in both
oxygenated and deoxygenated cells in the presence of ouabain and bu-
metanide (Fig. 3a). At both O2 tensions, residual K+ inﬂux was lower in
red cells fromHbSC patients compared to those fromHbSS patients. ISCs
probably account for the higher levels of residual K+ inﬂux in oxygenat-
ed red cells fromHbSSpatients (Fig. 3a). Levels in red cells fromboth ge-
notypes were increased by deoxygenation, as Psickle becomes activated,
more so in the latter than the former (0.99 ± 0.09 mmol.(l cell.h)−1,
n = 40, in red cells from HbSS patients cf. 0.34 ± 0.02 mmol.(l
cell.h)−1, n = 110, in those from HbSC individuals; p b 0.0001).
Gardos channel activity was also measured in fully oxygenated and
deoxygenated red cells (Fig. 4a). As for the residual K+ inﬂux, it showed
higher levels in deoxygenated red cells fromHbSS patients compared to
those from HbSC individuals (4.63 ± 0.51 mmol.(l cell.h)−1, n = 40, cf.
1.57 ± 0.12 mmol.(l cell.h)−1, n = 110; p b 0.0001). For both geno-
types, Gardos channel activity correlated positively with that of Psickle
(Fig. 4b: r = 0.433, p b 0.0001 for HbSC; r = 0.530, p = 0.0004, for
HbSS), although activities of bothwere higher in red cells fromhomozy-
gous HbSS patients compared to those from heterologous HbSC
individuals.
At intermediate oxygen tensions, further differences between red
cells fromHbSC andHbSS patients were apparent (Fig. 5). In both geno-
types, full deoxygenation elicitsmaximal levels of sickling, and activities
of Psickle and the Gardos channel. At an oxygen tension of 20mmHg, just
below the P50 for Hb, all three parameters were signiﬁcantly higher in
red cells fromHbSS patients. A similar trendwas also observed at an ox-
ygen tension of 40mmHg, just above the P50 for Hb. These ﬁndings sug-
gest that greater levels of hypoxia are required to induce the deleterious
morphological changes and K+ transport activities in red cells from
HbSC patients compared to those from HbSS.
Overall, sickling and activation of conductive K+movement through
Psickle and Gardos in red cells from HbSC patients followed the well
established pattern observed in red cells from homozygous HbSS pa-
tients (Joiner et al., 1993; Lew and Bookchin, 2005; Gibson, 2001).
Levels of K+ movement through the two channels, however, wereFig. 3. A comparision of Psickle activity and sickling in red cells from HbSS and HbSC pa-
tients. Red cells were treated as described in the legend to Fig. 2. (a) K+ inﬂux in Cl−
free saline in the presence of ouabain (100 μM), bumetanide (10 μM) and CLT (5 μM).
Psickle activity is calculated as the difference in K+ inﬂux at 0 and 100 mmHg.
(b) Sickling (%). Histograms represent means ± S.E.M., n = 110 for HbSC patients and
n = 40 for HbSS. *** p b 0.001.signiﬁcantly reduced in HbSC red cells, consistent with reduced partici-
pation of these transport systems in mediating solute loss and red cell
dehydration.
3.2. Activity and Regulation of the KCl Cotransporter in Red Cells FromHbSC
and HbSS Patients
Activity of the third transporter, KCC, mediating the obligatorily
coupled movement of K+ and Cl−, was also studied. In red cells from
HbSC patients, KCC activity was 0.77 ± 0.54 (n = 3), 1.76 ± 0.26
(n = 6) and 0.44 ± 0.23 mmol.(l cell.h)−1 (n = 6) at saline pHs of
6.5, 7.0 and 7.4, and therefore showed a similar bell-shaped relationship
to that seen in red cells from HbSS patients (Brugnara et al., 1986). Hy-
potonicity (265 mOsm cf. 295 mOsm) also increased KCC activity
(1.26 ± 0.4 mmol.(l cell.h)−1 in hypotonic saline cf. 0.44 ± 0.23 in iso-
tonic, n = 6) with the effects of hypotonicty and KCC peak activity at
pH 7.0 being additive (2.76 ± 0.38 mmol.(l cell.h)−1, n = 6). The com-
bined stimulus of low pH and swelling was selected for subsequent
experiments.
In the next series of experiments, the O2 dependence of KCC activity
was investigated. In the case of red cells from HbSC patients, activity of
KCC was highest in fully oxygenated red cells. As O2 tension was re-
duced, KCC activity also fell, showing a reciprocal response to that of
sickling and activation of Psickle and Gardos channel (Fig. 6 cf. Fig. 2a).
In this respect, its behaviour was like that of the transporter in red
cells from normal HbAA individuals (Gibson et al., 1998) – although at
a considerably highermagnitude overall (Hall and Ellory, 1986). By con-
trast, in HbSS red cells, although KCC activity initially reduces with O2
tension, it reachesminimal activity at about the P50 of Hb. It then usually
increases again, or remains stable, but does not fall further (Gibson et al.,
1998; Hannemann et al., 2014). The O2 dependence of KCC in HbSC and
HbSS are thus markedly different.
A summary of KCC activity in fully oxygenated (KCC100) and deoxy-
genated (KCC0) red cells from HbSC and HbSS patients is presented in
Fig. 7a. The difference in O2 dependence of KCC activity in red cells
from the two genotypes is emphasised, with KCC activity higher in oxy-
genated red cells from HbSC patients than those from HbSS individuals
(3.42±0.79mmol.(l cell.h)−1, n=110, inHbSC cf. 2.74±0.16mmol.(l
cell.h)−1, n = 40, in HbSS; p = 0.039), with the opposite pattern being
observed under deoxygenated conditions (0.79 ± 0.06 in HbSC cf.
1.96 ± 0.21 in HbSS; p b 0.0001). As well as being signiﬁcantly higher
in oxygenated red cells from HbSC patients, KCC activity was markedly
variable between HbSC patients, with a lowest value of 0.44 mmol.(l
cell.h)−1 and highest of 7.61. Therefore red cells from some HbSC indi-
viduals have particularly high levels of KCC activity, others present with
more modest levels. KCC correlated positively with age in both geno-
types, especially in KCC0 in red cells from HbSC patients (r = 0.614,
p b 0.0001). Functionally, KCC mediates volume decrease in reticulo-
cytes during red cell maturation and diminishes with red cell age (Hall
and Ellory, 1986) and reticulocyte % correlated to KCC100 (r = 540, p b
0.0001) and KCC0 (r = 0.28, p b 0.0032) in HbSC patients.
Increased cell volume is a well known stimulus for KCC activity
(Gibson and Ellory, 2003). In normal individuals, younger red cells
and reticulocytes are generally larger, less dense and also show higher
levels of KCC activity (Hall and Ellory, 1986). Similarly, the least dense
red cells from HbSS patients are enriched for reticulocytes and also for
higher levels of KCC activity (Brugnara et al., 1986). This occurs despite
the existence of so-called “fast-track” dehydrating reticulocytes
(Bookchin et al., 1991). The density distribution of red cells in HbSC pa-
tients differs. Thus the percentage of reticulocytes in HbSC patients is
greater in the denser fractions (Lawrence et al., 1991). In the ﬁnal set
of experiments, therefore, the total red cell populations were separated
on a density gradient into dense and light fractions, each containing
about a third of the total red cell population, and KCC activity measured
in both fractions. In red cells from HbSS patients, KCC activity was
higher in the lighter, more swollen fraction of red cells than in the
Fig. 4. A comparison of Gardos channel activity in red cells from HbSS and HbSC patients. Red cells were treated as described in the legend to Fig. 2. (a) Gardos channel activity (CLT-sen-
sitive K+ inﬂux in the presence of 100 μMouabain and 10 μMbumetanide) in fully oxygenated and fully deoxygenated red cells. Histograms represent means ± S.E.M., n= 110 for HbSC
patients and n= 40 for HbSS. ***p b 0.001. (b) Pearson correlation between Psickle and Gardos channel in HbSS andHbSC patients. Insert shows a higher resolution at lowermagnitudes of
activity of Psickle and Gardos channel. Correlations were calculated as r = 0.433 (p b 0.001) for HbSC red cells and r = 0.530 (p b 0.001) for HbSS.
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for red cells from HbSC patients such that, in this case, the denser frac-
tion had greater KCC activity. Red cells from the two density fractions
will differ in volume, which will affect the activity of a volume-
sensitive transport system like KCC. The two fractions were therefore
treated with nystatin prior to measurement of KCC activity, so that
both had the same initial volume and intracellular cation content. Fol-
lowing nystatin treatment, the higher levels of KCC activity in the dens-
er fraction of red cells from HbSC patients became more exaggerated.
These results are consistent with the postulate that denser circulating
red cells in HbSC patients have higher levels of KCC activity.
The above ﬁndings are consistent with a more prominent role for
KCC in solute loss, dehydration and shrinkage in red cells fromHbSC pa-
tients – which could explain the correlation between disease severityFig. 5. Oxygen dependence of sickling and conductive K+ pathways in red cells fromHbSS
and HbSC patients. Red cells were treated as described in the legend to Fig. 2. Sickling (%),
and Psickle and Gardos activities (mmol.(l cells.h)−1), were normalised to valuesmeasured
at 0mmHg (whichwere 75± 5%, 0.43± 0.06mmol.(l cells.h)−1 and 1.72± 0.47mmol.(l
cells.h)−1, respectively, for red cells fromHbSCpatients; and 80±2%, 0.82±0.11mmol.(l
cells.h)−1, 3.20±0.47mmol.(l cells.h)−1 for red cells fromHbSSpatients. Histograms rep-
resent means ± S.E.M., n = 6–8 for HbSC patients and n = 9–12 for HbSS patients.
**p b 0.01, *** b 0.001 HbSC cf. HbSS.and KCC activity in this group of patients. By contrast, the conductive
K+ pathways represented by Psickle and the Gardos channel would ap-
pear to be more involved in dehydration of red cells from SCA patients.
4. Discussion
The present ﬁndings show signiﬁcant differences in cation homeo-
stasis comparing red cells from HbSC and HbSS patients. The sickling
shape change occurred at higher levels of O2 tension in red cells from
HbSS than HbSC patients, together with activation of the main conduc-
tive cation channels, Psickle and theGardos channel. Both transport path-
ways showed a similar correlation with sickling. The level of activity of
the two channels was signiﬁcantly lower in HbSC cells compared to
HbSS ones, and also requiredmore profoundhypoxia to become activat-
ed, consistent with a reduced participation of these systems in mediat-
ing solute loss and dehydration. By contrast, KCC activity was
signiﬁcantly higher in oxygenated red cells from HbSC patients than
those from HbSS individuals. KCC activity varied considerably betweenFig. 6. A comparision of the oxygen dependence of KCl cotransport (KCC) activity, with
that of sickling, Psickle and Gardos activities, in red cells from HbSC patients. Red cells
were treated as described in the legend to Fig. 2. KCC activity was measured as the Cl−-
dependent K+ inﬂux in the presence of ouabain (100 μM), bumetanide (10 μM) and CLT
(5 μM), and normalised to that measured at 100 mmHg O2 (2.70 ± 0.58 mmol.(l
cells.h)−1, n = 4). Percentage sickling and the activities of Psickle and Gardos channel
were normalised to values measured at 0 mmHg (75 ± 5% for sickling; 0.43 ± 0.06
mmol.(l cells.h)−1 and 1.72 ± 0.47, n = 7, for Psickle and Gardos channel, respectively).
Data are presented as means ± S.E.M..
Fig. 7. KCC activity in red cells fromHbSC and HbSS patients. Red cells were treated as described in the legends to Fig. 2. (a) Cl−dependent K+ inﬂux in the presence of ouabain (100 μM),
bumetanide (10 μM) and CLT (5 μM). Histograms representmeans± S.E.M., n= 110 for HbSC patients, and n= 40 for HbSS, *p b 0.05, ***p b 0.001. (b) Pearson correlation between KCC
activity and age in red cells from HbSC patients. Correlations were calculated as r = 0.339 (p b 0.001) at 100 mmHg O2 and r = 0.614 (p b 0.001) at 0 mmHg.
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that observed in red cells from HbSS patients, being inactivated at low
O2 tension (as seen in normal HbAA red cells). There was a higher
level of activity of KCC in denser HbSC red cells compared to that ob-
served in lighter ones. Taken together, these ﬁndings are consistent
with a greater role for KCC in dehydration of red cells from HbSC pa-
tients. They also present a characteristic of red cell membrane transport
in HbSC patients which may be important in pathogenesis, and further
substantiate the hypothesis that HbSC disease is a different entity to
that of homozygous HbSS SCD.
Polymerisation of HbS initiates the clinical complications of SCD
(Bunn and Forget, 1986). The resulting sequelae are multiple and di-
verse, and their individual impact on pathogenesis is difﬁcult to eluci-
date. Early changes include altered red cell membrane permeability
(Gibson and Ellory, 2002; Lew and Bookchin, 2005; Tosteson, 1955;
Joiner, 1993). That red cells from SCD patients have elevated cation per-
meability, which can contribute to disease bymediating solute loss, de-
hydration and raised HbS concentration, has been established for some
time (Tosteson, 1955). The reduced lag time to polymerisation upon de-
oxygenation observed in shrunken red cells with elevated [HbS] is con-
sidered central to disease progression (Eaton and Hofrichter, 1987).Fig. 8. KCC activity in density separated red cell fractions from HbSS and HbSC patients.
Red cellswere density separated using OptiPrep gradients and either kept on ice or treated
with nystatin. They thenwere suspended at 20%Hct in Cl− free saline before being diluted
10-fold into test tubes formeasurement of K+ inﬂux. KCCwasmeasured as Cl−dependent
K+ inﬂux in the presence of ouabain (100 μM), bumetanide (10 μM) and CLT (5 μM).
(a) HbSS red cells. (b) HbSC red cells. Histograms represent means ± S.E.M., n = 6.
*p b 0.05, **p b 0.01 comparing KCC activity in light and dense fractions.Previous reports of cation transport in red cells from HbSC patients
have been published but studies were limited to a very small number
of individuals (Canessa et al., 1986; Olivieri et al., 1992; Gibson et al.,
2001). The present work investigates the behaviour of red cell samples
from over a hundred HbSC patients. Of the three transporters involved
in dehydration (Lew and Bookchin, 2005), the present ﬁndings are con-
sistent with a lesser role for Psickle and Gardos in HbSC disease, whilst
supporting a greater involvement of KCC activity (Table 1). The observa-
tion that KCC activity in red cells fromHbSC patients correlates with fre-
quency of hospitalisation (Rees et al., 2015), a marker of disease
severity, emphasises the importance of understanding in detail how
this transporter is regulated.
The molecular identity of KCC has been established with four iso-
forms identiﬁed to date, of which three (KCC1, 3 and 4) are found in
red cells (Gillen et al., 1996; Pellegrino et al., 1998). In addition, splice
variants do occur (Crable et al., 2005), whichmay be relevant to the dif-
ferent behaviour of KCC in red cells fromHbSS and HbSC patients. Phys-
iological regulation of KCC is also complex (Gibson and Ellory, 2003),
with evidence for cascades of protein kinases and phosphatases
(Cossins et al., 1994), acting on both serine–threonine and tyrosine res-
idues, impacting on transporter activity. This enzymatic regulation is
probably key to the differences in response to O2 (Gibson et al., 1994;
Merciris et al., 2001), perhaps interacting with Hb at the level of the
red cell membrane (Sega et al., 2012, 2015). This aspect, however, re-
mains to be fully elucidated.
Maintaining red cell hydration would reduce some of the complica-
tions of SCD through reducing the tendency for HbS to polymerise, and
represents a longstanding clinical goal (eg Rosa et al., 1980). This is par-
ticularly so in red cells from HbSC patients, in which HbS comprises
roughly only 50% of the total intracellular Hb. Hydration of these cells
would require only a modest increase to reduce the tendency of HbS
to polymerise (Fabry et al., 1982). Again, most work has been carriedTable 1
A comparison of sickling and themain potassium permeability pathways in red cells from
patients homozygous (HbSS) or heterozygous (HbSC) for sickle cell disease. See text for
detailed explanations.
Sickling Similar in both genotypes
Psickle Reduced in HbSC
Gardos Reduced in HbSC
KCl cotransport (KCC) Increased in HbSC
O2 dependence of KCC Increased in HbSC
Density dependence of KCC Higher in denser HbSC red cells
Higher in lighter HbSS red cells
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cessful strategy has been identiﬁcation of reagents which inhibit the
Gardos channel. Clotrimazole (Ellory et al., 1992), the in vitro inhibitor
employed in the current study, cannot be used clinically, as its imidazole
ring appears to cause hepatopathy (Brugnara et al., 1996). Analogues
such as ICA-17,043 (“senicapoc”) have progressed to clinical trials and
were successful at increasing red cell hydration in SCD patients
(Stocker et al., 2003; Ataga et al., 2008, 2011). Their use has been
discontinued as they were unable to reduce pain episodes. Partial Psickle
inhibitors also exist. They include anion exchange inhibitors such as the
stilbenes (Joiner, 1990), but the use of such compounds is precluded by
the wide distribution of these transporters through body tissues.
Dipyridamole, which is used clinically as an anti-thrombotic compound,
also partially reduces Psickle activity (Joiner et al., 2001), and has had
some success at reducing clinical signs of SCD (Chaplin et al., 1980;
Wun et al., 2013).
No speciﬁc inhibitor of KCChas progressed to clinical trials, however,
although compounds like H74 were shown to speciﬁcally target KCC
over the related Na+-K+-2Cl− cotransporter (NKCC) (Ellory et al.,
1990). This molecule, or its related analogues, represent compounds
of promise. SimpleMg2+ supplementation has also been used in limited
clinical trials, as elevated red cell Mg2+ inhibits KCC activity, with some
success (De Franceschi et al., 1997; De Franceschi et al., 2000). If KCC ac-
tivity is implicated as a key mechanism in pathogenesis, of particular
importance in HbSC patients, re-evaluation of potential KCC inhibitors
is warranted.
An alternative approach has involved the development of com-
pounds that directly interpolatewithHbSmolecules, to increase oxygen
afﬁnity and to reduce polymerisation upon deoxygenation. Aromatic al-
dehydes have shown promise and one of them, 5-hydroxymethyl-2-
furfural (5HMF), is currently in phase II clinical trials in SCD patients
in the US and UK (Abdulmalik et al., 2005; Stern et al., 2012; Health
NIH, 2013; Safo and Kato, 2014).Wehave recently shown that it has ad-
ditional effects on K+ transport, with inhibition of Psickle and Gardos
channel and increased hydration, in red cells from SCD patients
(Hannemann et al., 2014).
Finally, the marked variability in KCC activity between patients sug-
gests differences of clinical signiﬁcance in the genetic and molecular
control of the transporter when comparing different HbSC individuals.
Elucidation of these factors could provide the twin advantages of
informing drug design (to inhibit KCC, increase red cell hydration and
ameliorate the more severe complications of the disease) and also the
possible identiﬁcation of effective prognostic markers (to inform the
management of HbSC patients at an early stage).Acknowledgements
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